From translational research to clinical strategy, #AACR26 reinforced how quickly oncology continues to evolve.

We leave San Diego encouraged by the focus on targeted approaches and continued innovation across treatment pathways. See what’s next for $ATOS: https://t.co/KSRvn5G3Op https://t.co/Pc6KiXQGKd